GlassScriptPhysician profile
Craig D Mueller
NPI 1164448155
$7,532.30
in general payments reported to CMS, 2019-2025
40 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,949 · 2022: $1,658 · 2023: $1,494 · 2024: $1,022 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Debt Forgiveness: $18.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.17 |
| Debt Forgiveness | $18.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,832.04 | 2021-2025 | |
| Lilly USA, LLC | $904.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $608.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $603.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $364.56 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $278.63 | 2021-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $254.75 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $245.21 | 2021-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $210.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $184.79 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $179.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.32 | 2021-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $145.73 | 2021-2024 | Xarelto, Spravato |
| Amarin Pharma, INC. | $135.16 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $132.81 | 2023-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.